Major Outcomes in Moderately Hypercholesterolemic, Hypertensive Patients Randomized to Pravastatin vs Usual Care: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT-LLT)

2002 JAMA 1,323 citations

Abstract

Pravastatin did not reduce either all-cause mortality or CHD significantly when compared with usual care in older participants with well-controlled hypertension and moderately elevated LDL-C. The results may be due to the modest differential in total cholesterol (9.6%) and LDL-C (16.7%) between pravastatin and usual care compared with prior statin trials supporting cardiovascular disease prevention.

Keywords

MedicinePravastatinInternal medicineMyocardial infarctionRandomized controlled trialDiabetes mellitusCholesterolEndocrinology

MeSH Terms

AgedAnticholesteremic AgentsCardiovascular DiseasesCause of DeathFemaleHumansHydroxymethylglutaryl-CoA Reductase InhibitorsHypercholesterolemiaHypertensionLipidsMaleMiddle AgedPravastatinProportional Hazards ModelsRisk Factors

Affiliated Institutions

Related Publications

Publication Info

Year
2002
Type
article
Volume
288
Issue
23
Pages
2998-3007
Citations
1323
Access
Closed

Citation Metrics

1323
OpenAlex
6
Influential
1038
CrossRef

Cite This

Curt D. Furberg, Jackson T. Wright, Barry R. Davis et al. (2002). Major Outcomes in Moderately Hypercholesterolemic, Hypertensive Patients Randomized to Pravastatin vs Usual Care: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT-LLT). JAMA , 288 (23) , 2998-3007. https://doi.org/10.1001/jama.288.23.2998

Identifiers

DOI
10.1001/jama.288.23.2998
PMID
12479764

Data Quality

Data completeness: 90%